Overcoming autopsy barriers in pediatric cancer research.
Pediatr Blood Cancer., Feb;60(2):204-9 (2013)
Promise and pitfalls of quantitative imaging in oncology clinical trials.
Magn Reson Imaging., Nov;30(9):1301-12 (2012)
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Invest New Drugs., Apr (2012)
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
J. Clin. Oncol., Feb;30(5):507-12 (2012)
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Cancer., Feb;118(3):770-6 (2012)
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Oncology., 78(5-6):340-7 (2010)
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Cancer., Mar;116(5):1272-80 (2010)
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Anticancer Drugs., Apr;21(4):433-8 (2010)
A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
Invest New Drugs., Apr;29(2):374-9 (2011)
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Clin. Cancer Res., Nov;15(22):7099-105 (2009)
J. Urol., Dec;182(6):2675; dscussion 2676 (2009)
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
J. Clin. Oncol., Jun;27(17):2772-8 (2009)
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr
J. Clin. Oncol., Nov;26(33):5360-7 (2008)
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clin Genitourin Cancer., Sep;6(2):103-9 (2008)
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
BJU Int., Dec;102(11):1601-6 (2008)
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Clin Genitourin Cancer., Mar;6(1):36-9 (2008)
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Cancer., Jun;112(11):2377-83 (2008)
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
Cancer., Jun;112(11):2432-9 (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J. Clin. Oncol., Feb;26(4):626-32 (2008)
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Cancer., Feb;112(3):521-6 (2008)